X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding aims to support the clinical development of TILT-123 (igrelimogene litadenorepvec) in combination with pembrolizumab for the treatment platinum-resistant/refractory ovarian cancer patients.
Lead Product(s): Igrelimogene Litadenorepvec,Pembrolizumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 14, 2024
Details:
TILT-123 (igrelimogene litadenorepvec) is a 5/3 chimeric serotype adenovirus armed with two human cytokines, which is being evaluated in combination with avelumab for squamous cell carcinoma of head and neck, and melanoma.
Lead Product(s): Igrelimogene Litadenorepvec,Avelumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
The funding will be used to advance to Phase II the company’s combination trials of TILT-123 which use oncolytic immunotherapies synergistically with checkpoint inhibitors.
Lead Product(s): TILT-123,Avelumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Finland’s Lifeline Ventures
Deal Size: $23.8 million Upfront Cash: Undisclosed
Deal Type: Financing February 07, 2023
Details:
TILT-123 is a human 5/3 chimeric adenovirus that has been engineered for targeting, safety and potency, is an oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), designed to stimulate T cells to better fight cancer.
Lead Product(s): TILT-123
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.
Lead Product(s): TILT-123,Pembrolizumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
TILT Biotherapeutics has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.
Lead Product(s): TILT-123
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.
Lead Product(s): TILT-123,Pembrolizumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 14, 2021
Details:
Funds will be used to advance TILT's proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials in Europe and the United States, and to prepare for Phase 2 trials.
Lead Product(s): TILT-123,Tumor infiltrating lymphocytes
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lifeline Ventures
Deal Size: $6.9 million Upfront Cash: Undisclosed
Deal Type: Financing June 16, 2020
Details:
Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.
Lead Product(s): TILT-123
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biotheus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
